The UK National Screening Committee (UKNSC) has come under renewed criticism over its cautious stance on prostate cancer screening, with advocates and experts calling for more proactive measures to address what they describe as a growing public health concern.

The committee, which advises the Department of Health and Social Care on population screening programs, maintains that current prostate cancer screening policies should remain narrowly targeted based on available evidence. Professor Sir Mike Richards, chairman of the UKNSC, has defended the committee’s position, emphasizing confidence in the existing criteria and highlighting the committee’s broader success in saving an estimated 10,000 lives annually through various screening initiatives. However, this approach has disappointed campaigners who argue that it limits the potential to detect curable prostate cancer cases early.

The UKNSC’s cautious approach reflects a core principle articulated by several committee members, including Professor Anne Mackie, director of programmes for the UKNSC. She has repeatedly stressed that population screening must be grounded in robust evidence demonstrating an overall benefit and cautioned against overdiagnosis and overtreatment. Mackie has argued that early detection may not always be beneficial and could strain healthcare resources by identifying individuals who are not seriously ill. Other committee members, such as clinical genetics consultant Anneke Lucassen and public health professor Chris Hyde, have echoed this prudential stance, emphasizing harm reduction and the avoidance of unnecessary medical interventions in healthy individuals.

Critics outside the committee challenge this conservative stance, highlighting advances in diagnostic methods such as modern MRI, improved biopsy techniques, and risk-based testing that they say reduce the risks associated with screening. Martin Davies, chair of the Prostate Project charity, described the committee’s concerns about overdiagnosis and overtreatment as “out-of-date” given current clinical practices. David James of Prostate Cancer Research accused the UKNSC of being “static and backwards-looking,” arguing that the committee’s decision-making does not reflect recent technological and procedural developments.

A particularly contentious issue is the committee’s failure to recommend broader screening for higher-risk groups, including black men, who statistically face double the risk of developing prostate cancer. Consultant urologist Professor Frank Chinegwundoh and Professor Stephen Langley have criticized the UKNSC’s approach, describing it as a “grave mistake” that risks clinical negligence by treating high-risk populations no differently from the general population. The lack of diversity within the committee itself has also been highlighted; no black members currently serve on the UKNSC, which some say undermines its ability to address the specific needs of minority groups.

Prominent figures such as Oscar-winning director Sir Steve McQueen, whose father died of prostate cancer, have publicly condemned the committee’s position as “indefensible,” pointing to the potential impact that greater diversity and lived experience could have on decision-making.

While the UKNSC has not ruled out revising its policy in the future, observers note the committee’s history of slow progress on other cancer screening programs. For example, lung cancer screening was initially rejected in 2007 and only recommended in a targeted manner in 2022, years after its adoption in other countries.

As prostate cancer remains a leading cause of cancer-related deaths among men in the UK, patients, advocates, and clinicians are urging the committee to speed up its review and adopt more inclusive screening policies that reflect recent advances and address disparities in risk.